Ah, the annual fallback. Last year we rose on anticipation of FDA submission....then it didn't happen in Q1 and we drifted downward. Previously, we rose in March on Dupont news and again, drifted down when the news didn't translate into revenue.
We all know the story this year. but let's face it: we are a publically traded company. PRs and newsletters don't prop up share prices for vey long. What we need today is what we needed 1 and 2 years ago: $$$$$$$$ coming in from the big ideas.
DR said expect FDA approval in Q2. That's EXACTLY what I expect. And then I expect this company to move ahead like any other company in its sector, with revenue, expansion and earnings. I liked it a lot at .04 and I love it now.
If the LTC rollout happens as planned, 1-2 bucks will be a distant memory in 1-2 years
